Creekside Partners Purchases New Shares in iShares Biotechnology ETF (NASDAQ:IBB)

Creekside Partners acquired a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,700 shares of the financial services provider’s stock, valued at approximately $508,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IBB. BNP Paribas Financial Markets grew its holdings in shares of iShares Biotechnology ETF by 25.7% in the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock valued at $282,038,000 after acquiring an additional 420,053 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in iShares Biotechnology ETF by 2.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after purchasing an additional 14,535 shares during the period. Global Assets Advisory LLC purchased a new stake in shares of iShares Biotechnology ETF during the 1st quarter valued at $66,059,000. Raymond James Financial Services Advisors Inc. raised its stake in shares of iShares Biotechnology ETF by 24.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after purchasing an additional 42,822 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of iShares Biotechnology ETF by 5.3% in the 1st quarter. Commonwealth Equity Services LLC now owns 198,709 shares of the financial services provider’s stock worth $27,267,000 after buying an additional 10,033 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

IBB opened at $144.77 on Wednesday. iShares Biotechnology ETF has a fifty-two week low of $111.83 and a fifty-two week high of $150.57. The firm has a 50-day moving average of $145.68 and a 200 day moving average of $138.97.

iShares Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.